Explore

Trendline Trendline
SAGA Diagnostics Unveils Data on Pathlight MRD Test at ASCO 2026, Highlighting Cancer Treatment Advancements

SAGA Diagnostics Unveils Data on Pathlight MRD Test at ASCO 2026, Highlighting Cancer Treatment Advancements

SAGA Diagnostics Unveils Data on Pathlight MRD Test at ASCO 2026, Highlighting Cancer Treatment Advancements
Trendline Trendline
Agendia to Present FLEX Study Data at ASCO 2026, Enhancing Breast Cancer Treatment Guidelines

Agendia to Present FLEX Study Data at ASCO 2026, Enhancing Breast Cancer Treatment Guidelines

Agendia to Present FLEX Study Data at ASCO 2026, Enhancing Breast Cancer Treatment Guidelines
Trendline Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy
Trendline Trendline
SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026

SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026

SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026
Trendline Trendline
Exelixis to Present Key Findings on Cancer Treatments at ASCO 2026

Exelixis to Present Key Findings on Cancer Treatments at ASCO 2026

Exelixis to Present Key Findings on Cancer Treatments at ASCO 2026
Trendline Trendline
Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma

Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma

Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma
Trendline Trendline
Veracyte to Present at June 2026 Investor Conferences, Showcasing Cancer Diagnostics Innovations

Veracyte to Present at June 2026 Investor Conferences, Showcasing Cancer Diagnostics Innovations

Veracyte to Present at June 2026 Investor Conferences, Showcasing Cancer Diagnostics Innovations
Trendline Trendline
Veracyte to Engage in June 2026 Investor Conferences, Highlighting Diagnostic Innovations

Veracyte to Engage in June 2026 Investor Conferences, Highlighting Diagnostic Innovations

Veracyte to Engage in June 2026 Investor Conferences, Highlighting Diagnostic Innovations
Trendline Trendline
Discovery Life Sciences Launches IVDR-Compliant Genomic Service for EU Oncology Trials

Discovery Life Sciences Launches IVDR-Compliant Genomic Service for EU Oncology Trials

Discovery Life Sciences Launches IVDR-Compliant Genomic Service for EU Oncology Trials
Trendline Trendline
Discovery Life Sciences Introduces IVDR-Compliant Genomic Panel for EU Oncology Trials

Discovery Life Sciences Introduces IVDR-Compliant Genomic Panel for EU Oncology Trials

Discovery Life Sciences Introduces IVDR-Compliant Genomic Panel for EU Oncology Trials
Trendline Trendline
Personalis Expands Medicare Coverage for Breast Cancer Monitoring with NeXT Personal

Personalis Expands Medicare Coverage for Breast Cancer Monitoring with NeXT Personal

Personalis Expands Medicare Coverage for Breast Cancer Monitoring with NeXT Personal
Trendline Trendline
Veracyte Announces Participation in June 2026 Investor Conferences

Veracyte Announces Participation in June 2026 Investor Conferences

Veracyte Announces Participation in June 2026 Investor Conferences